Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	Jul 15	Data from 1960-1976 added to RDISCLOSURE
NEWS 5	Jul 21	Identification of STN records implemented
NEWS 6	Jul 21	Polymer class term count added to REGISTRY
NEWS 7	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 8	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 9	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 10	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 11	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 12	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 13	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS 14	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 15	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 16	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS 17	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS 18	SEP 22	DIPPR file reloaded
NEWS 19	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS 20	SEP 29	DISSABS now available on STN

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 14:44:56 ON 30 SEP 2003

=> file medline, uspatful, dgene, wpids, fsta, biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 14:45:19 ON 30 SEP 2003

FILE 'USPATFULL' ENTERED AT 14:45:19 ON 30 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:45:19 ON 30 SEP 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 14:45:19 ON 30 SEP 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 14:45:19 ON 30 SEP 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'BIOSIS' ENTERED AT 14:45:19 ON 30 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

=> e shimkets,r/au
E1            4      SHIMKETS RICHARD AUGUST/AU
E2            2      SHIMKETS RICK/AU
E3            0 --> SHIMKETS,R/AU
E4            2      SHIMKEVICH A L/AU
E5            2      SHIMKEVICH A M/AU
E6            3      SHIMKEVICH ALEXANDER LVOVICH/AU
E7            2      SHIMKEVICH ANDREY M/AU
E8           12      SHIMKEVICH I A/AU
E9            2      SHIMKEVICH L D/AU
E10          86      SHIMKEVICH L L/AU
E11           6      SHIMKEVICH R L/AU
E12           1      SHIMKEVICH S V/AU

=> s e1
L1            4 "SHIMKETS RICHARD AUGUST"/AU

=> s e2
L2            2 "SHIMKETS RICK"/AU

=> d l1 ti abs ibib tot

L1   ANSWER 1 OF 4  USPATFULL on STN
TI     Atrial natriuretic factor mutants and ischemic stroke
AB     The present invention is based upon the observation that a mutant atrial
       natriuretic factor (ANF) gene increases stroke latency in spontaneously
       hypertensive rats-stroke prone (SHRSP). Accordingly, the present
       invention provides methods using mutant ANF proteins, fragments,
       analogs, derivatives and homologs of mutant ANF proteins, the nucleic
       acids encoding these mutant ANF proteins, as well as modulators of ANF
       for treating or preventing ischemic diseases, in particular ischemic
       stroke. The invention also relates to methods of diagnosis, prognosis
       and screening for a disposition for diseases and disorders associated
       with increased levels of ANF. Pharmaceutical compositions, methods of
       screening for ANF mutants and ANF modulators with utility for treatment
       and prevention of ischemic stroke are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       2003:33456  USPATFULL
```

TITLE: Atrial natriuretic factor mutants and ischemic stroke
INVENTOR(S): **Shimkets, Richard August**, West Haven, CT, United States
PATENT ASSIGNEE(S): CuraGen Corporation, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6514939	B1	20030204
APPLICATION INFO.:	US 1999-428929		19991028 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-916043, filed on 21 Aug 1997, now patented, Pat. No. US 6013630
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Allen, Marianne P.
LEGAL REPRESENTATIVE: Mintz Levin, Biswas, Naomi S., Elrifi, Ivor R.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2353
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 4 USPATFULL on STN
TI Atrial natriuretic factor mutants and ischemic stroke
AB The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:4792 USPATFULL
TITLE: Atrial natriuretic factor mutants and ischemic stroke
INVENTOR(S): **Shimkets, Richard August**, West Haven, CT, United States
PATENT ASSIGNEE(S): CuraGen Corporation, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013630		20000111
APPLICATION INFO.:	US 1997-916043		19970821 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Allen, Marianne P.
LEGAL REPRESENTATIVE: Elrifi, Ivor R.Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C., Johnson, David E.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Atrial natriuretic factor mutants and ischemic stroke.
AB The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously

hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.

ACCESSION NUMBER: 2003:129778 BIOSIS
DOCUMENT NUMBER: PREV200300129778
TITLE: Atrial natriuretic factor mutants and ischemic stroke.
AUTHOR(S): **Shimkets, Richard August**
ASSIGNEE: CuraGen Corporation
PATENT INFORMATION: US 6514939 February 04, 2003
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Feb. 4 2003) Vol. 1267, No. 1, pp. No Pagination. http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English

L1 ANSWER 4 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Atrial natriuretic factor mutants and ischemic stroke.
AB The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.
ACCESSION NUMBER: 2000:319969 BIOSIS
DOCUMENT NUMBER: PREV200000319969
TITLE: Atrial natriuretic factor mutants and ischemic stroke.
AUTHOR(S): **Shimkets, Richard August (1)**
CORPORATE SOURCE: (1) West Haven, CT USA
ASSIGNEE: CuraGen Corporation, New Haven, CT, USA
PATENT INFORMATION: US 6013630 January 11, 2000
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Jan. 11, 2000) Vol. 1230, No. 2, pp. No pagination. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Novel G-protein-coupled receptors: Structure and tissue expression analysis.
AB The G-protein-coupled receptors (GPCRs) are cell surface molecules that transmit extracellular signals to intracellular messengers. The GPCR gene family is the largest known receptor family including an estimated 700-1000 odorant GPCRs. The ligands that bind GPCRs are small and can be easily mimicked by use of synthetic analogues making GPCRs ideal targets for the development of therapeutic agents. We have identified several

hundred GPCR-like genes in our effort to characterize novel drug targets. These genes undergo a systematic analysis. The genes are first cloned and then tissue expression profiles generated for both normal and disease conditions. Extensive in silico analysis of these genes is conducted at both the nucleotide and amino acid level to determine the homology and secondary structure. The tissue expression profiles are correlated with the DNA sequence for each gene to enable us to distinguish the non-expressed pseudogenes. Additional analysis is directed towards the study of the upstream DNA sequence from multiple GPCRs with similar tissue-expression profiles. This sequence is then evaluated for conserved residues/motifs/domains which may be associated with potential regulatory and promoter regions that define tissue-specific expression profiles. Results from these analyses will be presented.

ACCESSION NUMBER: 2001:514720 BIOSIS
DOCUMENT NUMBER: PREV200100514720
TITLE: Novel G-protein-coupled receptors: Structure and tissue expression analysis.
AUTHOR(S): Padigaru, Muralidhara (1); Taupier, Ray (1); Zerhusen, Bryan (1); Herrmann, John (1); Burgess, Catherine (1); Braverman, Mike (1); Leach, Martin (1); Shenoy, Suresh (1); **Shimkets, Rick (1)**
CORPORATE SOURCE: (1) CuraGen Corporation, Branford, CT USA
SOURCE: International Genome Sequencing and Analysis Conference, (2000) Vol. 12, pp. 82. print.
Meeting Info.: 12th International Genome Sequencing and Analysis Conference Miami Beach, Florida, USA September 12-15, 2000
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L2 ANSWER 2 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Prioritization of targets by in silico profile generation.
AB Genes differentially expressed between normal and diseased states offer an attractive target for drug-based intervention. CuraGen's proprietary gene expression technologies (SeqCalling, GeneCalling, Pharmacogenomics) employ a sophisticated bioinformatics platform that leads to the rapid identification of potential human disease targets and toxicology markers. The GeneCalling and Pharmacogenomics processes compare the gene expression of defined animal, tissue or cellular models of disease or drug-response to appropriate controls. For both of these methods, identification of differentially expressed genes does not require prior knowledge of gene sequence, a direct contrast to conventional chip-based technologies. Downstream sequence analysis of these potential targets is supplemented by cutting-edge genomics technologies and our proprietary human sequence database consisting of more than 4 million sequences. Target selection is further refined through the integration of the target's gene expression profile with our extensive protein:protein interaction database and high-throughput tissue distribution characterization. A completed profile of the selected target can therefore be rapidly and inversely engineered from the gene expression data. This dramatically reduces the non-productive consumption of resources while increasing the efficiency of selection. Further validation by wet-lab analysis is thereby directed toward targets that have the highest potential for downstream drug development or therapeutic intervention.

ACCESSION NUMBER: 2001:494515 BIOSIS
DOCUMENT NUMBER: PREV200100494515
TITLE: Prioritization of targets by in silico profile generation.
AUTHOR(S): Burgess, Catherine (1); Braverman, Mike (1); Leach, Martin (1); Gould-Rothberg, Bonnie (1); **Shimkets, Rick (1)**
CORPORATE SOURCE: (1) CuraGen Corporation, Branford, CT USA
SOURCE: International Genome Sequencing and Analysis Conference, (2000) Vol. 12, pp. 52. print.
Meeting Info.: 12th International Genome Sequencing and

```
                    Analysis Conference Miami Beach, Florida, USA September
                    12-15, 2000
DOCUMENT TYPE:      Conference
LANGUAGE:           English
SUMMARY LANGUAGE:   English


=> d his

     (FILE 'HOME' ENTERED AT 14:44:56 ON 30 SEP 2003)

     FILE 'MEDLINE, USPATFULL, DGENE, WPIDS, FSTA, BIOSIS' ENTERED AT 14:45:19
     ON 30 SEP 2003
               E SHIMKETS,R/AU
L1           4 S E1
L2           2 S E2

=> e fernandes, e/au
E1           1     FERNANDES Z Z/AU
E2           5     FERNANDES ZSCHABER R M/AU
E3           0 --> FERNANDES, E/AU
E4          10     FERNANDESALNEMRI T/AU
E5           1     FERNANDESHJDE B/AU
E6           1     FERNANDESM J M/AU
E7           1     FERNANDEX A/AU
E8           1     FERNANDEX C/AU
E9           1     FERNANDEX DE LA VEGA CARLOS SANCHEZ/AU
E10          1     FERNANDEX DEL PALACIO M J/AU
E11          1     FERNANDEX E GARCIA/AU
E12          1     FERNANDEX FERNANDEZ M/AU

=> s PROX polypeptide
L3           2 PROX POLYPEPTIDE

=> d l3 ti abs ibib tot

L3   ANSWER 1 OF 2  USPATFULL on STN
TI     Novel amino acid sequences for human fetal brain-like polypeptides
AB     This application is drawn to novel amino acid sequences for mammalian
       polypeptides that have sequence similarity to fetal brain tissue
       protein. The polypeptides are novel secreted proteins 649 amino acids in
       length.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       2003:4266  USPATFULL
TITLE:                  Novel amino acid sequences for human fetal brain-like
                        polypeptides
INVENTOR(S):            Shimkets, Richard A., West Haven, CT, UNITED STATES
                        Fernandes, Elma, Branford, CT, UNITED STATES
PATENT ASSIGNEE(S):     CuraGen Corporation, New Haven, CT (U.S. corporation)

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 2003004310      A1   20030102
APPLICATION INFO.:      US 2001-4551       A1   20011205  (10)
RELATED APPLN. INFO.:   Continuation of Ser. No. US 2000-635949, filed on 10
                        Aug 2000, PENDING

                              NUMBER         DATE
                        ------------------ --------
PRIORITY INFORMATION:   US 1999-148433P    19990811 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY AND POPEO, P.C.,
```

One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 6347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 2 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
TI Nucleic acids encoding secreted polypeptides, designated PROX polypeptides, useful for treating a syndrome associated with a PROX-associated disorder, e.g. cancer.
AN 2001-147509 [15] WPIDS
AB WO 200110902 A UPAB: 20011129
NOVELTY - Isolated nucleic acids encoding secreted polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where X is an integer from 1 to 17), are new.

DETAILED DESCRIPTION - Isolated nucleic acids encoding secreted polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where X is an integer from 1 to 17), are new.

A nucleic acid (N1) encoding a **PROX polypeptide** is selected from:

(a) a nucleic acid encoding a mature form of a polypeptide selected from one of the 17 amino acid sequences (P1) defined in the specification;

(b) a nucleic acid encoding a variant of a mature form of a sequence selected from P1, where one or more amino acid residues differ from the sequence of the mature form, provided that the variant differs in no more than 15% of the residues from the sequence of the mature form;

(c) a nucleic acid encoding an amino acid sequence selected from P1;

(d) a nucleic acid encoding a variant of a sequence selected from P1, where one or more amino acid residues differ from the sequence of the mature form, provided that the variant differs in no more than 15% of the residues from the amino acid sequence selected from P1;

(e) a nucleic acid fragment encoding at least a portion of an amino acid sequence selected from P1, or a variant of the polypeptide, where one or more residues in the variant differs from the sequence of the mature form, provided that the variant differs in no more than 15% of the residues from the amino acid sequence selected from P1; or

(f) a nucleic acid comprising the complement of (a)-(e).

INDEPENDENT CLAIMS are also included for the following:

(1) an isolated polypeptide (P2) comprising an amino acid sequence selected from:

(a) a mature form of a polypeptide selected from P1;

(b) a variant of a mature form of a sequence selected from P1, where one or more amino acid residues differ from the sequence of the mature form, provided that the variant differs in no more than 15% of the residues from the sequence of the mature form;

(c) an amino acid sequence selected from P1;

(d) a variant of a sequence selected from P1, where one or more amino acid residues differ from the sequence of the mature form, provided that the variant differs in no more than 15% of the residues from the amino acid sequence selected from P1;

(2) a vector comprising N1 operably linked to a promoter;

(3) a cell comprising the vector of (2);

(4) an antibody (Ab1) that immunospecifically binds to P2;

(5) a method of determining the presence or amount of P2 in a sample, comprising:

(a) contacting the sample with Ab1; and

(b) determining the presence or amount of Ab1 bound to the polypeptide, therefore determining the presence or amount of P2 in the sample;

(6) a method of determining the presence or amount of N1 in a sample, comprising:

(a) contacting the sample with a probe that binds to N1; and

(b) determining the presence or amount of the probe bound to the

nucleic acid;

(7) a method of identifying an agent that binds to P2, comprising contacting the polypeptide with the agent and determining whether the agent binds to the polypeptide;

(8) a method of identifying an agent that modulates the expression or activity of P2, comprising:

(a) providing a cell expressing the polypeptide;

(b) contacting the cell with the agent; and

(c) determining whether the agent modulates expression or activity of the polypeptide, where an alteration in expression or activity of the polypeptide indicates that the agent modulates expression or activity of the polypeptide;

(9) a method for modulating the activity of P2, comprising contacting a cell sample expressing P2 with a compound that binds to the polypeptide in an amount sufficient to modulate the activity if the polypeptide;

(10) a method of treating or preventing a PROX-associated disorder in a human, comprising administering P2, N1 or Ab1;

(11) a kit comprising P2, N1 or Ab1;

(12) a method (M1) for screening for a modulator of activity or of latency or predisposition to a PROX-associated disorder, comprising:

(a) administering a test compound to a test animal at increased risk for a PROX-associated disorder, where the test animal recombinantly expresses P2;

(b) measuring the activity of the polypeptide in the test animal after administering the test compound; and

(c) comparing the activity of the protein in the test animal with the activity of the polypeptide in a control animal not administered the compound, where a change in the activity of the polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of or predisposition to a PROX-associated disorder;

(13) a method for determining the presence of or predisposition to a disease associated with altered levels of P2 in a first mammalian subject, comprising:

(a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and

(b) comparing the amount of the polypeptide in the sample of step (a) to the amount of polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to the disease, where an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease;

(14) a method for determining the presence of or predisposition to a disease associated with altered levels of N1 in a first mammalian subject;

(15) a method of treating a pathological state in a mammal, comprising administering a polypeptide in an amount that is sufficient to alleviate the pathological state, where the polypeptide has a sequence at least 95% identical to a polypeptide comprising an amino acid sequence selected from P1, or its biologically active fragment; and

(16) a method of treating a pathological state in a mammal, comprising administering Ab1 in an amount that is sufficient to alleviate the pathological state.

ACTIVITY - Cytostatic; Immunomodulatory; reproduction general.

No biological data given.

MECHANISM OF ACTION - Gene therapy; PROX antagonist; PROX agonist.

USE - The PROX polypeptide, nucleic acid and antibody are useful in the manufacture of a medicament for treating a syndrome associated with a PROX-associated disorder (claimed), e.g. a cell proliferation and/or differentiation disorder (e.g. cancer or immune associated disorders) and a gestational disease (e.g. pre-clampsia).

They are also used for screening for a modulator of activity or of latency or predisposition to a PROX-associated disorder.

Dwg.0/9

ACCESSION NUMBER: 2001-147509 [15] WPIDS
DOC. NO. CPI: C2001-043750

TITLE: Nucleic acids encoding secreted polypeptides, designated PROX polypeptides, useful for treating a syndrome associated with a PROX-associated disorder, e.g. cancer.

DERWENT CLASS: B04 D16

INVENTOR(S): FERNANDES, E; SHIMKETS, R A

PATENT ASSIGNEE(S): (CURA-N) CURAGEN CORP

COUNTRY COUNT: 95

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001010902	A2	20010215	(200115)*	EN	166
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000068997	A	20010305	(200130)		
EP 1218406	A1	20020703	(200251)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
US 2003004310	A1	20030102	(200305)		
JP 2003508030	W	20030304	(200319)		236

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2001010902	A2		WO 2000-US21857	20000811
AU 2000068997	A		AU 2000-68997	20000811
EP 1218406	A1		EP 2000-957365	20000811
			WO 2000-US21857	20000811
US 2003004310	A1	Provisional	US 1999-148433P	19990811
		Cont of	US 2000-635949	20000810
			US 2001-4551	20011205
JP 2003508030	W		WO 2000-US21857	20000811
			JP 2001-515709	20000811

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000068997	A	Based on	WO 2001010902
EP 1218406	A1	Based on	WO 2001010902
JP 2003508030	W	Based on	WO 2001010902

PRIORITY APPLN. INFO: US 2000-635949 20000810; US 1999-148433P 19990811; US 2001-4551 20011205

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
15 and L7	0

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L8

Refine Search

Recall Text | Clear

Search History

DATE: Tuesday, September 30, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L8	l5 and L7	0	L8
L7	l1 and L6	15	L7
L6	fernandes.in.	193	L6
L5	l1 and L4	5	L5
L4	Shimkets.in.	6	L4
L3	protease inhibitor and L2	36064	L3
L2	L1 and cancer	17499	L2
L1	PROX polypeptide	43127	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 15 returned.

☐ 1. Document ID: US 6566505 B2

L7: Entry 1 of 15 File: USPT May 20, 2003

US-PAT-NO: 6566505
DOCUMENT-IDENTIFIER: US 6566505 B2

TITLE: Antibodies to Mch6 polypeptides

DATE-ISSUED: May 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Bryn Mawr	PA		

US-CL-CURRENT: 530/387.9; 530/388.26, 530/389.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 6462175 B1

L7: Entry 2 of 15 File: USPT Oct 8, 2002

US-PAT-NO: 6462175
DOCUMENT-IDENTIFIER: US 6462175 B1

TITLE: Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		
Armstrong; Robert	San Diego	CA		
Tomaselli; Kevin	La Jolla	CA		

US-CL-CURRENT: 530/350; 435/226, 530/300

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 6455296 B2

L7: Entry 3 of 15 File: USPT Sep 24, 2002

US-PAT-NO: 6455296
DOCUMENT-IDENTIFIER: US 6455296 B2

TITLE: Apoptotic protease Mch6, nucleic acids encoding same and methods of use

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		

US-CL-CURRENT: 435/226; 435/219

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 6287795 B1

L7: Entry 4 of 15 File: USPT Sep 11, 2001

US-PAT-NO: 6287795
DOCUMENT-IDENTIFIER: US 6287795 B1

TITLE: Mch4 and Mch5, apoptotic protease, nucleic acids encoding and methods of use

DATE-ISSUED: September 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		
Armstrong; Robert	San Diego	CA		
Tomaselli; Kevin	La Jolla	CA		

US-CL-CURRENT: 435/23; 435/219, 435/325, 435/7.21, 435/7.72, 435/7.91, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 6274318 B1

L7: Entry 5 of 15 File: USPT Aug 14, 2001

US-PAT-NO: 6274318
DOCUMENT-IDENTIFIER: US 6274318 B1
**** See image for Certificate of Correction ****

TITLE: Apoptotic protease Mch6, nucleic acids encoding same and methods of us

DATE-ISSUED: August 14, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		

US-CL-CURRENT: 435/6; 435/226, 435/23, 435/7.6, 435/7.71, 435/7.72, 435/7.9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 6. Document ID: US 6271361 B1

L7: Entry 6 of 15 File: USPT Aug 7, 2001

US-PAT-NO: 6271361
DOCUMENT-IDENTIFIER: US 6271361 B1

TITLE: Apoptotic protease Mch6, nucleic acids encoding same and methods of use

DATE-ISSUED: August 7, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		

US-CL-CURRENT: 536/23.2; 435/226, 435/320.1, 435/69.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 7. Document ID: US 5861498 A

L7: Entry 7 of 15 File: USPT Jan 19, 1999

US-PAT-NO: 5861498
DOCUMENT-IDENTIFIER: US 5861498 A
**** See image for Certificate of Correction ****

TITLE: Nucleotides encoding immunophilin FKBP46 and fragments thereof

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		

US-CL-CURRENT: 536/23.5; 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 8. Document ID: US 5858778 A

L7: Entry 8 of 15 File: USPT Jan 12, 1999

US-PAT-NO: 5858778
DOCUMENT-IDENTIFIER: US 5858778 A

TITLE: SF caspase-1 and compositions for making and methods of using the same

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Bryn Mawr	PA		

US-CL-CURRENT: 435/325; 435/219, 435/252.3, 435/252.33, 435/254.11, 435/320.1, 435/348, 536/23.2, 536/24.3, 536/24.31

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 9. Document ID: US 5851815 A

L7: Entry 9 of 15 File: USPT Dec 22, 1998

US-PAT-NO: 5851815
DOCUMENT-IDENTIFIER: US 5851815 A

TITLE: MCH4 and MCH5, apoptotic proteases

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		
Armstrong; Robert	San Diego	CA		
Tomaselli; Kevin	La Jolla	CA		

US-CL-CURRENT: 435/219; 435/183, 435/212, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw. Desc | Image

---

☐ 10. Document ID: US 5786173 A

L7: Entry 10 of 15 File: USPT Jul 28, 1998

US-PAT-NO: 5786173
DOCUMENT-IDENTIFIER: US 5786173 A

TITLE: MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use

DATE-ISSUED: July 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		
Armstrong; Robert	San Diego	CA		
Tomaselli; Kevin	La Jolla	CA		

US-CL-CURRENT: 435/69.1; 435/183, 435/219, 435/252.3, 435/320.1, 435/70.1, 530/324, 530/350, 536/23.1, 536/23.5, 536/24.31

Terms	Documents
11 and L6	15

WEST

Generate Collection | Print

Search Results - Record(s) 11 through 15 of 15 returned.

☐ 11. Document ID: US 5702699 A

L7: Entry 11 of 15 File: USPT Dec 30, 1997

US-PAT-NO: 5702699
DOCUMENT-IDENTIFIER: US 5702699 A

TITLE: Process for the recovery of lipophilic proteins

DATE-ISSUED: December 30, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanisch; Wolfgang H.	Oakland	CA		
Fernandes; Peter	Walnut Creek	CA		

US-CL-CURRENT: 424/85.6; 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 12. Document ID: US 5643566 A

L7: Entry 12 of 15 File: USPT Jul 1, 1997

US-PAT-NO: 5643566
DOCUMENT-IDENTIFIER: US 5643566 A

TITLE: Formulation processes for lipophilic proteins

DATE-ISSUED: July 1, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanisch; Wolfgang H.	Balmoral Heights			AU
Fernandes; Pete M.	Walnut Creek	CA		
Taforo; Terrance	Oakland	CA		
Thomson; James W.	Albany	CA		

US-CL-CURRENT: 424/85.4; 424/85.2, 424/85.6, 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 13. Document ID: US 4992271 A

L7: Entry 13 of 15 File: USPT Feb 12, 1991

US-PAT-NO: 4992271

DOCUMENT-IDENTIFIER: US 4992271 A

TITLE: Formulation for lipophilic IL-2 proteins

DATE-ISSUED: February 12, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanisch; Wolfgang H.	Oakland	CA		
Fernandes; Peter M.	Walnut Creek	CA		
Taforo; Terrance	Oakland	CA		

US-CL-CURRENT: 424/85.2; 424/85.1, 424/85.4, 424/85.5, 424/85.6, 424/85.7, 435/811, 514/12, 514/2, 514/21, 514/8, 514/885, 514/970, 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 14. Document ID: US 4569910 A

L7: Entry 14 of 15 File: USPT Feb 11, 1986

US-PAT-NO: 4569910
DOCUMENT-IDENTIFIER: US 4569910 A

TITLE: Methods and reagents for pyranosone production

DATE-ISSUED: February 11, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koths; Kirston E.	Berkeley	CA		
Halenbeck; Robert F.	San Rafael	CA		
Fernandes; Peter M.	Walnut Creek	CA		

US-CL-CURRENT: 435/105; 435/190, 435/911

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

---

☐ 15. Document ID: US 4462940 A

L7: Entry 15 of 15 File: USPT Jul 31, 1984

US-PAT-NO: 4462940
DOCUMENT-IDENTIFIER: US 4462940 A

TITLE: Process for the recovery of human .beta.-interferon-like polypeptides

DATE-ISSUED: July 31, 1984

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanisch; Wolfgang H.	Oakland	CA		
Fernandes; Peter M.	Lafayette	CA		

US-CL-CURRENT: 530/351; 424/85.6, 435/69.51, 435/811, 530/417, 530/424, 530/808,

530/825

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Terms	Documents
l1 and L6	15

Display Format: CIT | Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 6610480 B1

L5: Entry 1 of 5 File: USPT Aug 26, 2003

US-PAT-NO: 6610480
DOCUMENT-IDENTIFIER: US 6610480 B1

TITLE: Treatment and diagnosis of cardiac hypertrophy

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shimkets; Richard A.	West Haven	CT		
Lowe; David G.	Hillsborough	CA		

US-CL-CURRENT: 435/6; 536/23.1, 536/24.3, 536/24.31, 536/25.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

☐ 2. Document ID: US 6537554 B1

L5: Entry 2 of 5 File: USPT Mar 25, 2003

US-PAT-NO: 6537554
DOCUMENT-IDENTIFIER: US 6537554 B1

TITLE: Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shimkets; Richard A.	West Haven	CT		
Jeffers; Michael	Branford	CT		

US-CL-CURRENT: 424/198.1; 424/184.1, 435/4, 436/64

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

☐ 3. Document ID: US 6514939 B1

L5: Entry 3 of 5 File: USPT Feb 4, 2003

US-PAT-NO: 6514939
DOCUMENT-IDENTIFIER: US 6514939 B1

TITLE: Atrial natriuretic factor mutants and ischemic stroke

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shimkets; Richard August	West Haven	CT		

US-CL-CURRENT: 514/12; 530/324, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 6486299 B1

L5: Entry 4 of 5 File: USPT Nov 26, 2002

US-PAT-NO: 6486299
DOCUMENT-IDENTIFIER: US 6486299 B1

TITLE: Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shimkets; Richard A.	West Haven	CT		

US-CL-CURRENT: 530/350; 530/380, 530/800

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 6013630 A

L5: Entry 5 of 5 File: USPT Jan 11, 2000

US-PAT-NO: 6013630
DOCUMENT-IDENTIFIER: US 6013630 A

TITLE: Atrial natriuretic factor mutants and ischemic stroke

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shimkets; Richard August	West Haven	CT		

US-CL-CURRENT: 514/12; 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

Generate Collection Print

Terms	Documents
l1 and L4	5

Display Format: CIT Change Format

Previous Page Next Page